Clozaril Withdrawal & Tapering Guide
clozapine
Boxed Warning
Severe neutropenia/agranulocytosis (REMS-required ANC monitoring), orthostatic hypotension/cardiovascular and respiratory effects, seizures, myocarditis and cardiomyopathy, increased mortality in elderly with dementia-related psychosis.
In short
Clozaril (clozapine) is an Atypical Antipsychotic with a half-life of ~12 hours. Very slow taper essential. Withdrawal symptoms, when they occur, usually begin 1-3 days after stopping and settle within 4-8 weeks. It is also sold as FazaClo, Versacloz.
- Class
- Atypical Antipsychotic
- Half-life
- ~12 hours
- Common doses
- 12.5mg, 25mg, 50mg, 100mg, 200mg tablets; orally disintegrating
- Withdrawal onset
- 1-3 days after stopping
- Typical resolution
- 4-8 weeks
Educational reference only. Dose changes are decided with the prescriber who knows your history.
Overview
Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia and reduces suicide risk in schizophrenia. Reserved for treatment-resistant cases because of severe agranulocytosis risk requiring lifelong blood monitoring (REMS program).
12.5mg, 25mg, 50mg, 100mg, 200mg tablets; orally disintegrating
Tablets: 25mg, 100mg; ODT: 12.5mg, 25mg, 100mg, 150mg, 200mg; Oral suspension: 50mg/mL
Category B
Mechanism of Action
D2 antagonist (modest), strong 5-HT2A, M1, alpha-1, H1 antagonism. Broad receptor profile — drives both efficacy and side-effect burden.
Taper Notes
Very slow taper essential. Rebound psychosis on clozapine discontinuation can be more severe than original presentation. Coordinate with hematology and the REMS program.
Hyperbolic Tapering Guidance
Clozapine is unique — discontinuation should not be attempted without a clear plan and continuous mood/psychosis monitoring.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Withdrawal Timeline
1-3 days after stopping
1-2 weeks
4-8 weeks
Risk of supersensitivity psychosis after stopping is real and well-described
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- Smoking cessation — increases clozapine levels (CYP1A2 induction loss)
- Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) — markedly increase levels
- Other agranulocytosis-risk drugs (carbamazepine) — contraindicated
Contraindications
- History of clozapine-induced agranulocytosis
- Active myeloproliferative disorder
- Uncontrolled epilepsy
Toxicity
Agranulocytosis (~1%), myocarditis, seizures (dose-dependent), severe constipation/ileus, hypersalivation, weight gain, metabolic syndrome, orthostasis, sedation, NMS.
Pharmacokinetics
ADME Profile
Hepatic via CYP1A2 (major), CYP3A4, CYP2D6.
~97%
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
The arithmetic of a proportional reduction
The Maudsley Deprescribing Guidelines and NICE NG222 describe reducing Atypical Antipsychotic medications by a proportion of the previous dose rather than by a fixed amount, so each cut is smaller than the last. The table shows what that arithmetic produces at 10% per step, using 50 mg only as a worked example. How large each step is, how long it is held, and whether this pattern applies at all are decisions for the person and their prescriber.
| Step | % of starting dose | Worked example (50 mg start) |
|---|---|---|
| Start | 100% | 50 mg |
| Step 1 | 90% | 45 mg |
| Step 2 | 81% | 40.5 mg |
| Step 3 | 73% | 36.5 mg |
| Step 4 | 66% | 32.8 mg |
| Step 5 | 59% | 29.5 mg |
| Step 6 | 53% | 26.6 mg |
| Step 7 | 48% | 23.9 mg |
| Step 8 | 43% | 21.5 mg |
This is an illustration of a published method, not a schedule for anyone. It does not account for how long you have taken Clozaril, your current dose, formulation, or history. TaperCommunity does not recommend doses or dose changes; those are agreed with your prescriber.
Frequently asked questions about Clozaril
What are the withdrawal symptoms of Clozaril (clozapine)?
Common withdrawal symptoms of Clozaril (clozapine) include: rebound psychosis (often severe and rapid), cholinergic rebound, GI upset, agitation, insomnia. Symptom severity varies by individual, dose, and duration of use.
How should I taper off Clozaril (clozapine)?
Very slow taper essential. Rebound psychosis on clozapine discontinuation can be more severe than original presentation. Coordinate with hematology and the REMS program. Clozapine is unique — discontinuation should not be attempted without a clear plan and continuous mood/psychosis monitoring.
How long does Clozaril withdrawal last?
Clozaril withdrawal typically begins 1-3 days after stopping, peaks around 1-2 weeks, and resolves within 4-8 weeks. Risk of supersensitivity psychosis after stopping is real and well-described
Can I stop Clozaril cold turkey?
Stopping Clozaril abruptly is not recommended. Its half-life is ~12 hours, and the receptor adaptations built up during treatment do not reverse at that speed, so a sudden stop tends to produce the sharpest withdrawal. Prescribing guidance favours gradual, proportional reductions agreed with your prescriber.
How long does Clozaril stay in your system?
Clozaril (clozapine) has a half-life of ~12 hours. A drug is mostly cleared after about five half-lives, so Clozaril is largely out of the body about 3 days after the last dose, longer in older adults or with liver or kidney impairment. Withdrawal symptoms often begin before the drug has fully cleared and continue after it has, because the adaptations the brain made during treatment reverse more slowly than the drug leaves the blood.
Sources & References
Clozaril (clozapine) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D 2021 — A method for tapering antipsychotic treatment that may minimize the risk of relapse (Schizophrenia Bulletin)
- Tranter R, Healy D 1998 — Antipsychotic withdrawal symptoms: phenomenology and pathophysiology (Journal of Psychopharmacology)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Royal College of Psychiatrists — Antipsychotics — UK clinical guidance on antipsychotic prescribing and discontinuation
- Council for Evidence-Based Psychiatry (CEP UK) — Evidence-based critique of long-term antipsychotic prescribing
- Deprescribing.org — Antipsychotic deprescribing algorithm for insomnia and BPSD
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — antipsychotic tapering forum — Community archive of antipsychotic taper experiences
- Mad in America — antipsychotic archive — Independent journalism on antipsychotics and withdrawal
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- RxISK — adverse drug reaction reporting — Independent database of antipsychotic adverse-effect reports
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.